Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA

NCT05070845 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05070845
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05070845 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AN INTERVENTIONAL PHASE 2, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-06835375 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE PRIMARY IMMUNE THROMBOCYTOPENIA
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Recruiting
Start date
February 2, 2022
Completion date
August 2, 2028
Enrollment
91 (estimated)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

primary immune thrombocytopenia